Calu-3 was established from the pleural effusion of a 25-year-old Caucasian male patient with lung adenocarcinoma; this patient had previously been treated with cyclophosphamide, bleomycin, and doxorubicin. Calu-3 cells are capable of forming tumors when inoculated into nude mice and can also serve as a host for transfection.